ABSTRACT Pseudotumor cerebri syndrome (PTCS) is characterized by elevated intracranial pressure in the absence of intracranial mass lesions, structural abnormalities, or infectious conditions. Although the exact pathogenesis of PTCS remains largely elusive, it is increasingly recognized as a multifactorial condition. Identifying secondary contributors is essential for guiding etiology‐specific management and achieving an optimal treatment response. Essential thrombocythemia (ET) is a myeloproliferative neoplasm involving sustained thrombocytosis and an elevated risk of thrombotic complications. We present a case of PTCS associated with ET. In this instance, significant symptomatic relief coincided with the initiation of antiplatelet and cytoreductive therapy. This clinical trajectory suggests a potential synergistic association between ET‐related hematologic changes and the development of PTCS.
Chang et al. (Tue,) studied this question.